Skip to content

Released May 6, 2021, after the close

10-Q filed May 6, 2021, 36 days after period end · 0001564590-21-024932

Q1 2021 · 10-Q
Revenue$7.30M+4,219.5% vs Q1 2020no prior Q4 2020 on file
Net Income-$19.40MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.66N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$19,403,000N/M
Operating Cash Flow-$15,479,000N/M
Margins · derived
Operating margin-265.8%+13237.8 pt vs Q1 2020
Net margin-265.8%+13521.2 pt vs Q1 2020

What the release said

The release

Same quarter

MetricQ1 2021Q1 2020Q1 2019Q1 2018
Revenue$7.30M$169.00K$3.81M$1.15M
Net Income-$19.40M-$23.30M-$5.10M-$10.64M
EPS Diluted-$0.66-$1.22-$0.29-$0.74

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR